1-3 of 3
Susan Blumel, RN, BSN
Close
Sort by
Journal Articles

Combination of Ublituximab, TGR-1202, and Bendamustine Demonstrates Significant Activity in Patients with Advanced DLBCL and Follicular Lymphoma

Matthew Lunning, DO, Philip J Bierman, MD, R. Gregory Bociek, MD, Marshall T. Schreeder, MD, Susan Blumel, RN, BSN, Kathy Cutter, RN, BSN, Emily K. Pauli, BMBS, PharmD, Peter Sportelli, Hari P. Miskin, MS, Michael S. Weiss, Julie M Vose, MD
Journal: Blood
Blood (2016) 128 (22): 4197.
https://doi.org/10.1182/blood.V128.22.4197.4197
Published: 2016
Journal Articles

Ublituximab + TGR-1202 Demonstrates Activity and a Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL: Phase I Results

Matthew A. Lunning, DO, Julie Vose, Nathan Fowler, MD, Loretta Nastoupil, MD, Jan A. Burger, MD PhD, William Wierda, MD PhD, Marshall T. Schreeder, MD, Tanya Siddiqi, MD, Christopher Flowers, MD, Jonathon B. Cohen, MD, Susan Blumel, RN, BSN, Myra Miguel, RN, Kathy Cutter, RN, BSN, Emily K. Pauli, BMBS, PharmD, Ryan Handy, BS, Peter Sportelli, Hari P. Miskin, MS, Michael S. Weiss, Susan O'Brien, MD
Journal: Blood
Blood (2015) 126 (23): 1538.
https://doi.org/10.1182/blood.V126.23.1538.1538
Published: 2015
Journal Articles

Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Combination with TGR-1202, a Next Generation Once Daily PI3kδ Inhibitor, Demonstrates Activity in Heavily Pre-Treated and High-Risk Chronic Lymphocytic Leukemia (CLL) and B-Cell Lymphoma

Matthew A. Lunning, DO, Julie M. Vose, MD MBA, Marshall T. Schreeder, MD, Nathan Fowler, MD, Loretta J. Nastoupil, MD, Tanya Siddiqi, MD, Susan Blumel, RN, BSN, Emily K. Pauli, BMBS, PharmD, Kathy Cutter, RN, BSN, Warner Tse, RN, Hari P. Miskin, MS, Peter Sportelli, Michael S. Weiss, Swaroop Vakkalanka, PhD, Srikant Viswanadha, PhD, Susan O'Brien, MD
Journal: Blood
Blood (2014) 124 (21): 801.
https://doi.org/10.1182/blood.V124.21.801.801
Published: 2014